Announcement on the plan for shareholding increase by shareholders holding more than 5% of Hangzhou Tianmushan Pharmaceutical Co., Ltd.
Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the company\'s issuance of A-shares to specific targets obtained approval from the Laoshan District Finance Bureau of Qingdao
Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the voluntary commitment of 5% or more of majority shareholders not to reduce their holdings of the company
Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the progress of the majority shareholders\' agreement to transfer the company\'s shares to complete registration, transfer, and change of control
Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the progress of more than 5% of the majority shareholders of the company signed a supplementary agreement to the “Share Transfer Agreement” and a change in control
Hangzhou Tianmushan Pharmaceutical\'s announcement on the proposed changes in the company\'s controlling shareholders and actual controllers and the signing of supplementary agreements and control changes to the “Share Transfer Agreement”
Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the proposed change in the company\'s controlling shareholder and actual controller and the signing of the “Share Transfer Agreement” and the change of control
Hangzhou Tianmushan Pharmaceutical Co., Ltd. Equity Change Report (Yongxinhuarui)
Hangzhou Tianmushan Pharmaceutical Co., Ltd. Simplified Equity Change Report (Yuanjia Medical)
Verification and analysis report on Hangzhou Tianmushan Pharmaceutical Co., Ltd.\'s 2023 plan to issue A-shares to specific targets
Prompt announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the disclosure of the company\'s plan to issue A-shares to specific targets in 2023
Written review opinions of the Board of Supervisors of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on matters relating to the company\'s issuance of shares to specific targets
Verification and analysis report on Hangzhou Tianmushan Pharmaceutical Co., Ltd.\'s 2023 plan to issue A-shares to specific targets
Hangzhou Tianmushan Pharmaceutical Co., Ltd.\'s shareholder dividend return plan for the next three years (2023-2025)
Reminder of Hangzhou Tianmushan Pharmaceutical Co., Ltd. regarding proposed changes in the company\'s controlling shareholder and actual controller and signing the “Share Transfer Agreement” and the “Share Subscription Agreement with Conditions Effective”
Proposal for Hangzhou Tianmushan Pharmaceutical Co., Ltd.\'s plan to issue A-shares to specific targets in 2023
Announcement on diluted immediate returns and filling measures for issuing A-shares to specific targets in 2023 and commitments made by related entities
Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on providing financial support or compensation to investors who issued shares to specific targets and did not participate directly or through stakeholders in the subscription in 2023
Hangzhou Tianmu Pharmaceutical Co., Ltd. Detailed Equity Change Report (Huilong Huase)
Announcement of Hangzhou Tianmushan Pharmaceutical Co., Ltd. on the illegal reduction of the company\'s stock holdings by more than 5% by shareholders and an apology
No Data
No Data